In this study, we confidently identified the marker combination of EEF1G + MSLN + BCAM + TAGLN2 which showed upregulation in both serum and tissue an outperforming marker panel against currently available markers for ovarian cancer. This evidence concerns the gene TAGLN2 and ovarian cancer.